Pfizer profit doubles, but anti-smoking drug sags

NEW YORK - Pfizer Inc on Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.